Phase 1
Completed N=17
Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
Source: ClinicalTrials.gov NCT05210504 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcomePrimary: Change in Level of 13C 2-AAA in Plasma — 1.742 uM*Hr
Summary
This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Level of 13C 2-AAA in Plasma |
1.742 | — |
| PRIMARY Change in Level of 2-AAA in Urine |
7.69 | — |
Eligibility Criteria
Inclusion Criteria
-Prior participant in 2-AAA Dietary study.
Exclusion Criteria
- Newly diagnosed disease, including cardiovascular, renal, liver disease, or Diabetes mellitus.
- Individuals who are pregnant or lactating.
- Inability to provide written or electronic informed consent.
- Inability to fast for 8 hours.
Data sourced from ClinicalTrials.gov (NCT05210504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.